| Species |
Human |
| Protein Construction |
SLAMF6/NTB-A (Gln22-Met226)_x000D_
Accession # Q96DU3-1 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized SLAMF6/NTB-A hFc Chimera, Human at 1μg/ml (100μl/well) on the plate can bind Biotinylated AntiSLAMF6 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
49.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 60-75 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
SLAMF6 (signaling lymphocyte activation molecule 6) (Ly108 in mice, NTB-A or SF2000 in humans) is a homophilic receptor belonging to the superfamily immunoglobulin (Ig) domain-containing molecules. It is known to be widely and exclusively expressed on hematopoietic cells. The SLAMF6 intracellular portion is characterized by two ITSMs that act as binding sites for adaptor molecules such as SAP and EAT-2. |
| Synonyms |
ANK-T-B-antigen; NTB-A; CD352; SLAMF6; KALI; Ly108; NK-T-B-antigen; KALIb; SF2000 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
